1LO6
 
 | | Human Kallikrein 6 (hK6) active form with benzamidine inhibitor at 1.56 A resolution | | Descriptor: | BENZAMIDINE, Kallikrein 6, MAGNESIUM ION | | Authors: | Bernett, M.J, Blaber, S.I, Scarisbrick, I.A, Dhanarajan, P, Thompson, S.M, Blaber, M. | | Deposit date: | 2002-05-06 | | Release date: | 2002-05-15 | | Last modified: | 2023-08-16 | | Method: | X-RAY DIFFRACTION (1.56 Å) | | Cite: | Crystal structure and biochemical characterization of human kallikrein 6 reveals a
trypsin-like kallikrein is expressed in the central nervous system
To be Published
|
|
1L2E
 | | Human Kallikrein 6 (hK6) Active Form with benzamidine inhibitor | | Descriptor: | BENZAMIDINE, Kallikrein 6, MAGNESIUM ION | | Authors: | Bernett, M.J, Blaber, S.I, Scarisbrick, I.A, Blaber, M. | | Deposit date: | 2002-02-20 | | Release date: | 2002-05-08 | | Last modified: | 2023-08-16 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.
J.Biol.Chem., 277, 2002
|
|
1RG8
 | |
1SPJ
 | | STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ACETIC ACID, CALCIUM ION, ... | | Authors: | Laxmikanthan, G, Blaber, S.I, Bernett, M.J, Blaber, M. | | Deposit date: | 2004-03-16 | | Release date: | 2005-01-25 | | Last modified: | 2021-10-27 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | 1.70 A X-ray structure of human apo kallikrein 1: Structural changes upon peptide inhibitor/substrate binding
Proteins, 58, 2005
|
|
8UCD
 | | Cryo-EM structure of human STEAP1 in complex with AMG 509 Fab | | Descriptor: | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, AMG 509 anti-STEAP1 Fab, heavy chain, ... | | Authors: | Li, F, Bailis, J.M, Zhang, H. | | Deposit date: | 2023-09-26 | | Release date: | 2023-11-22 | | Last modified: | 2024-01-24 | | Method: | ELECTRON MICROSCOPY (3 Å) | | Cite: | AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Cancer Discov, 14, 2024
|
|
2ERM
 | | Solution structure of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue | | Descriptor: | 2-deoxy-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid-(1-4)-2-acetamido-2-deoxy-6-O-sulfo-alpha-D-glucopyranose-(1-4)-alpha-L-idopyranuronic acid-(1-4)-2-deoxy-2-(sulfoamino)-alpha-D-glucopyranose-(1-4)-2-O-sulfo-alpha-L-idopyranuronic acid, Heparin-binding growth factor 1, ISOPROPYL ALCOHOL | | Authors: | Canales, A, Lozano, R, Nieto, P.M, Martin-Lomas, M, Gimenez-Gallego, G, Jimenez-Barbero, J. | | Deposit date: | 2005-10-25 | | Release date: | 2006-10-03 | | Last modified: | 2020-07-29 | | Method: | SOLUTION NMR | | Cite: | Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
Febs J., 273, 2006
|
|
